- Home
- TSHA vs GILT Comparison
TSHA vs GILT Comparison
Compare TSHA & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- GILT
- Stock Information
- Founded
- TSHA 2019
- GILT 1987
- Country
- TSHA United States
- GILT Israel
- Employees
- TSHA N/A
- GILT N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- GILT Radio And Television Broadcasting And Communications Equipment
- Sector
- TSHA Health Care
- GILT Technology
- Exchange
- TSHA Nasdaq
- GILT Nasdaq
- Market Cap
- TSHA 397.8M
- GILT 381.2M
- IPO Year
- TSHA 2020
- GILT 1993
- Fundamental
- Price
- TSHA $2.71
- GILT $5.57
- Analyst Decision
- TSHA Strong Buy
- GILT Strong Buy
- Analyst Count
- TSHA 7
- GILT 2
- Target Price
- TSHA $7.00
- GILT $8.50
- AVG Volume (30 Days)
- TSHA 5.2M
- GILT 401.3K
- Earning Date
- TSHA 05-15-2025
- GILT 05-19-2025
- Dividend Yield
- TSHA N/A
- GILT N/A
- EPS Growth
- TSHA N/A
- GILT N/A
- EPS
- TSHA N/A
- GILT 0.24
- Revenue
- TSHA $7,224,000.00
- GILT $321,407,000.00
- Revenue This Year
- TSHA N/A
- GILT $45.29
- Revenue Next Year
- TSHA N/A
- GILT $11.74
- P/E Ratio
- TSHA N/A
- GILT $23.21
- Revenue Growth
- TSHA N/A
- GILT 13.49
- 52 Week Low
- TSHA $1.05
- GILT $4.04
- 52 Week High
- TSHA $4.32
- GILT $8.05
- Technical
- Relative Strength Index (RSI)
- TSHA 60.38
- GILT 35.60
- Support Level
- TSHA $2.44
- GILT $5.43
- Resistance Level
- TSHA $2.95
- GILT $5.95
- Average True Range (ATR)
- TSHA 0.25
- GILT 0.22
- MACD
- TSHA -0.02
- GILT -0.08
- Stochastic Oscillator
- TSHA 51.60
- GILT 10.37
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.